21 completed, 5 recruiting, 4 active not recruiting, 4 not yet recruiting. 16 Phase 2, 14 Phase 3, 8 Phase 1, 2 Not applicable.
Follow PENTA Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl) - HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario 12 de Octubre | 87 | 2027-01-01 | 2026-08-20 |
| Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2) Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS - HIV -1 Infection | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario 12 de Octubre | 73 | 2027-01-01 | 2026-08-20 |
| An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Dolutegravir (DTG), Abacavir (ABC), Lamivudine (3TC) - HIV Infection | Phase 3 | Not yet recruiting | University College, London | 800 | 2026-11-01 | 2026-08-28 |
| A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus zelicapavir, Placebo - RSV Infection, RSV | Phase 2 | Recruiting | Enanta Pharmaceuticals, Inc | 150 | 2026-07-09 | 2026-07-20 |
| Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination. Abrysvo, Nirsevimab - RSV Immunization | Phase 3 | Not yet recruiting | PENTA Foundation | 1500 | 2025-09-01 | 2025-06-27 |
| Safety, Pharmacokinetics, and Antiviral Activity of Remdesivir (VEKLURY®) in Hospitalized Children With RSV Remdesivir - Respiratory Syncytial Virus (RSV) | Phase 2 | Recruiting | PENTA Foundation | 120 | 2025-07-16 | 2025-07-23 |
| Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN standard regimen (Administered as PEP) - Neonate, Maternal Transmission | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 359 | 2025-06-23 | 2026-01-30 |
| Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC MVA-BN standard regimen, MVA-BN half-dose regimen - Mpox (Monkeypox), Vaccination | Phase 3 | Active not recruiting | Jean-Pierre Van geertruyden | 344 | 2025-05-29 | 2026-04-29 |
| Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract Infection Urinary Tract Infections | Withdrawn | PENTA Foundation | 2025-03-11 | 2025-04-18 | ||
| Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV DRV/r FDC (120/20mg) - HIV Infections | Phase 1 / Phase 2 | Withdrawn | PENTA Foundation | 2025-02-01 | 2026-03-05 | |
| UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children dolutegravir (DTG)/emtricitabine (FTC)/tenofovir alafenamide (TAF) regimen, Dolutegravir (DTG)/ Emtricitabine (FTC)/tenofovir alafenamide (TAF) - HIV Infection | Phase 2 | Completed | PENTA Foundation | 53 | 2024-12-11 | 2026-03-04 |
| Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU. Optimised kangaroo care - Infection, Bacterial, Infection Prevention | Not applicable | Recruiting | PENTA Foundation | 3080 | 2024-05-28 | 2026-03-25 |
| Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV No intervention - Monkeypox, HIV Coinfection | Completed | NEAT ID Foundation | 2000 | 2023-12-01 | 2025-08-13 | |
| Long-Acting Treatment in Adolescents (LATA) Cabotegravir, Rilpivirine Drug Combination, TLD - Hiv, HIV Infections | Phase 3 | Unknown | University College, London | 476 | 2023-06-22 | 2024-04-29 |
| Mpox Paediatric and Adolescent Clinical Study Monkey Pox, Monkeypox | Completed | PENTA Foundation | 1108 | 2023-03-17 | 2026-08-31 | |
| Safety and Pharmacokinetics Evaluation of Fostemsavir + (OBT) in HIV-1 Infected Children and Adolescents Who Are Failing Their cART and Have Dual- or Triple-class Antiretroviral Resistance Fostemsavir - HIV Infections With Multi Drug Resistant Virus | Phase 1 / Phase 2 | Active not recruiting | PENTA Foundation | 60 | 2022-06-30 | 2026-03-05 |
| DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to <15 Years Old Dolutegravir (DTG) and lamivudine (3TC), SOC - HIV Infections | Phase 2 / Phase 3 | Active not recruiting | PENTA Foundation | 386 | 2022-04-22 | 2026-03-04 |
| Safety and Effects of Using Prime-boost HIVIS DNA and MVA-CMDR Vaccine Regimens With or Without Toll-like Receptor 4 Agonist on HIV Reservoirs in Perinatally HIV Infected Children and Youth HIVIS DNA/MVA-CMDR, HIVIS DNA + Cervarix and MVA-CMDR, Cervarix - HIV Infections | Phase 1 | Completed | Henry M. Jackson Foundation for the Advancement of Military Medicine | 25 | 2022-02-18 | 2025-08-11 |
| Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms BioFire FilmArray Respiratory Panel 2.1 plus (RP2.1plus) - Community-acquired Acute Lower Respiratory Infection | Not applicable | Completed | PENTA Foundation | 522 | 2021-07-07 | 2025-04-18 |
| Monitoring COVID-19 Vaccination Response in Fragile Populations COVID-19 vaccination - SARS CoV 2 Infection, Vaccination; Infection | Completed | University of Bologna | 8894 | 2021-05-24 | 2025-03-25 |
Showing 20 of 40. Sign in to see all of them.
HIV Infections (17) · COVID-19 (4) · Mpox, Monkeypox (4) · Acquired Immunodeficiency Syndrome (3) · Communicable Diseases (2) · Infections (2) · Neonatal Sepsis (2) · Respiratory Syncytial Virus Infections (2) · Sepsis (2) · Smallpox (2) · Tuberculosis (2) · Bacterial Infections (1) · Breakthrough Infections (1) · Community-Acquired Pneumonia (1) · Cross Infection (1)
dolutegravir (4) · abacavir (3) · Broadly Neutralizing Antibodies (2) · Emtricitabine (2) · Lamivudine (2) · Meropenem (2) · Racivir (2) · Ritonavir (2) · Sodium Chloride (2) · efavirenz (2) · Adenosine Monophosphate (1) · Albendazole (1) · Ampicillin (1) · Antitubercular Agents (1) · Art Therapy (1)
United Kingdom (16) · Spain (14) · Uganda (10) · Italy (9) · South Africa (9) · Thailand (8) · Germany (7) · Zimbabwe (7) · France (5) · Greece (5) · Netherlands (5) · Switzerland (4) · United States (4) · Belgium (3) · Democratic Republic of the Congo (3)
Julia Bielicki, PhD (2) · Albert Faye (1) · Alfredo Tagarro, MD (1) · Ann J. Melvin, MD (1) · Cinta Moraleda, MD, PhD (1) · David M Burger, PharmD PhD (1) · Diana Gibb (1) · Diana M Gibb (1) · Giovanni Montini, Prof. (1) · Hermione Lyall, MD (1) · Intira J Collins, PhD (1) · Irja Lutsar (1) · J van Drongelen (1)
PMID 21288774, PMID 23169329, PMID 24413315, PMID 24992294, PMID 25326090, PMID 25944344, PMID 26202768, PMID 27540363, PMID 28213595, PMID 28595298, PMID 29653915, PMID 29684092, PMID 30513108, PMID 30530925, PMID 32103260, PMID 32103268, PMID 32330231, PMID 32763217, PMID 33446115, PMID 34432828, PMID 34817414, PMID 34843669, PMID 34965338, PMID 35761406, PMID 35868341, PMID 36055295, PMID 36724434, PMID 37289666, PMID 37304494, PMID 37578953, PMID 37766218, PMID 37766505, PMID 38183019, PMID 38190418, PMID 38636725, PMID 38670622, PMID 39909979, PMID 39978387, PMID 40307889, PMID 41512916, PMID 41579881, PMID 41735855, PMID 41749274, PMID 42016921, PMID 42372625, PMID 42468541, PMID 42521300, PMID 42705257, PMID 42753775
2009 (2), 2005 (1), 2014 (1), 2019 (1), 2025 (1)